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M A J O R A R T I C L E
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Background. Severe malarial anemia (SMA) remains a major cause of pediatric illness and mortality in Sub-
Saharan Africa. Here we test the hypothesis that prenatal exposures, reﬂected by soluble inﬂammatory mediators
in cord blood, can condition an individual’s susceptibility to SMA.
Methods. In a Tanzanian birth cohort (n = 743), we measured cord blood concentrations of tumor necrosis fac-
tor (TNF), TNF receptors I and II (TNF-RI and TNF-RII), interleukin (IL)-1β, IL-4, IL-5, IL-6, IL-10, and interferon
gamma (IFN-γ). After adjusting for conventional covariates, we calculated the hazard ratios (HR) for time to ﬁrst
SMA event with log(e) cytokine concentrations dichotomized at the median, by quartile, and per standard deviation
(SD) increase.
Results. Low levels of TNF, TNF-RI, IL-1β, and IL-5 and high levels of TNF-RII were associated statistically
signiﬁcantly and respectively with approximately 3-fold, 2-fold, 8-fold, 4-fold, and 3-fold increased risks of SMA
(Hb < 50 g/L). TNF, TNF-RI, and IL-1β concentrations were inversely and log-linearly associated with SMA risk;
the HR (95% conﬁdence interval [CI]) per 1-SD increase were respectively 0.81 (.65, 1.02), 0.76 (.62, .92), and
0.50 (.40, .62).
Conclusions. These data suggest that proinﬂammatory cytokine levels at birth are inversely associated with SMA
risk and support the hypothesis that pediatric malarial disease has fetal origins.
Keywords. malaria; anemia; cord blood; inﬂammation; cytokines; developmental programming; risk marker.
Infections by Plasmodium falciparum cause the deaths
of an estimated half-million African infants and chil-
dren every year [1]. Variations in ecology, diversity of
host and parasitic factors, and disparities in treatment
contribute to the signiﬁcant heterogeneity in the
incidence, severity, and manifestations of malarial dis-
ease. In regions of holoendemic transmission, severe
malarial anemia (SMA) is the dominant malarial syn-
drome and predominantly occurs in children <2 years
of age [2]. Overall, the burden of SMA in Sub-Saharan
Africa is substantial: data from a multicenter study sug-
gest that severe anemia affects approximately one-ﬁfth
of pediatric P. falciparum hospitalizations and is associ-
ated with a case fatality risk of 8.4% [3].
The pathophysiological process of SMA is complex.
During an acute malaria episode, hemolysis and splenic
retention of both parasitized and healthy erythrocytes,
along with acute iron sequestration and dyserythro-
poietic changes, directly drive reductions in the host’s
hemoglobin (Hb) concentrations [4–6]. Moreover, per-
turbations in the timing and magnitude of the host’s in-
nate immune response can inﬂuence the efﬁcacy of a
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host’s erythropoietic response [7]. Immunological observations
from humans and animal malaria models have begun to eluci-
date the complex and exquisitely sensitive pathways mediated
by cytokines, growth factors, and effector molecules that con-
tribute to the etiology of SMA [7–14].Perkins et al [15] and oth-
ers have proposed that the distinctly dysregulated inﬂammatory
proﬁle of SMA is caused by the interaction between parasitic
products, including P. falciparum-derived hemozoin, DNA, gly-
cosylphosphotidylinositols, and antigens, and speciﬁc charac-
teristics of the host’s innate immune system.
Nevertheless, the host characteristics that predispose certain
individuals to SMA remain uncertain. Comorbid infections and
chronic hematinic deﬁciencies can contribute to bone marrow
suppression and a blunted erythropoietic response in malarial
anemia. Furthermore, genetic investigations have identiﬁed
moderate relations between numerous cytokine promoter poly-
morphisms and haplotypes and susceptibility to SMA (eg,
Kempaiah et al [16], Okeyo et al [12]) in addition to the well-
characterized effects of hemoglobinopathies (reviewed in Taylor
et al [17]). There is also growing evidence that prenatal expo-
sures and the intrauterine environment may modulate cytokine
production and inﬂuence malaria risk [18–20]. Transplacental
exposure to P. falciparum antigens can sensitize and, in some
cases, tolerize the child’s Toll-like receptor-mediated and ac-
quired immune responses to parasitic products with implica-
tions for malaria and anemia risk later in life [21–24]. In
addition, initial investigations in the study population for this
report have found inverse associations between levels of inter-
leukin 1β (IL-1β) and tumor necrosis factor (TNF) at birth and
risk of all-cause severe malaria during infancy [25].
In this prospective cohort study of infants born in a region of
perennial malaria transmission in the United Republic of
Tanzania, we test the hypothesis that prenatal exposures or
intrinsic predispositions, reﬂected by soluble inﬂammatory me-
diators in cord blood, can condition an individual’s susceptibil-
ity to SMA. Speciﬁcally, we investigate the strength, biological
gradient, and speciﬁcity of the association with SMA in the
ﬁrst 4 years of life. The cytokines, receptors, and ratios investi-
gated here were selected because of their known associations
with acute SMA episodes, eythropoietic suppression, and ery-
throid precursor maturation.
METHODS
Study Population
The Mother-Offspring Malaria Studies (MOMS) Project was
initiated in 2002 in a region of perennial malaria transmission
in northeastern Tanzania. Human immunodeﬁciency virus
(HIV)-negative, pregnant women who presented for delivery
at hospitals and antenatal care clinics in the catchment area
of the Muheza Designated District Hospital, Tanga region,
were invited consecutively to participate in the study. Figure 1
provides a ﬂow diagram illustrating the selection of the study
population. A total of 1045 pregnant women between the
Figure 1. Selection of study population. Abbreviation: HIV, human immunodeﬁciency virus.
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ages of 18 and 45 years were recruited to the MOMS Project be-
tween 9 September 2002 and 13 October 2005. Participating
mothers provided informed consent for themselves and for
their participating newborn child. Of the 1045 potential preg-
nancies, 882 singleton, HIV-negative, and sickle cell disease-
free children participated in baseline data collection and were
followed up until 18 May 2006.
Trained project nurses and assistant medical ofﬁcers admin-
istered questionnaires and collected clinical information using
standardized forms. All children were monitored for incident
SMA by clinicians during routine visits on a biweekly basis
during the ﬁrst 12 months of life and a monthly basis for any
follow-up beyond the ﬁrst year (median (interquartile range
[IQR]) for total duration of follow-up in weeks: 104 (56,
152)). Prompt care was provided to sick children in accordance
with Tanzanian Ministry of Health protocols. The primary out-
come of this analysis was time in days to ﬁrst SMA event. SMA
cases have been deﬁned as a positive blood smear for P. falcip-
arum in the presence of Hb <50 g/L to meet World Health
Organization (WHO) criteria and <60 g/L for the standard def-
inition used in earlier publications on the pathogenesis of SMA
[8, 9, 12, 14, 16]. The US National Institutes of Health (NIH)
International Clinical Studies Review Committee of the Divi-
sion of Microbiology and Infectious Diseases approved the
study procedures, and the Institutional Review Boards of the
Seattle Biomedical Research Institute and the National Institute
for Medical Research in Tanzania provided ethical clearance.
Laboratory Measurements
Cord blood samples were collected immediately following par-
turition using routine procedures for cord clamping and cannu-
lating umbilical blood vessels. Blood samples were treated with
EDTA for anticoagulation and fractionated by centrifugation at
3000 g for 3 minutes. Cord blood plasma samples were frozen at
−70°C until the immunoassays were performed. Technicians
blinded to participants’ disease status used commercially avail-
able multiplex, bead-based platforms and custom-made assay
kits, as previously described, to measure cytokines [25]. The de-
tection limits in the measurement of the cytokines were: TNF,
0.10 pg/mL; TNF-RI, 1.58 pg/mL; TNF-RII, 0.21 pg/mL; IL-1β,
0.01 pg/mL; IL-4, 0.3 pg/mL; IL-5, 0.02 pg/mL; IL-6, 1.45 pg/mL;
IL-10, 0.02 pg/mL; and interferon γ (IFN-γ), 0.04 pg/mL. Sickle
cell trait was determined by electrophoresis. Parasitemia was
determined by Giemsa-stained thick blood smears of samples
collected by heel and ﬁnger prick during child visits. Hemo-
grams were measured using an impedance-based analyzer.
Statistical Analysis
All statistical analyses were performed using Stata - version 12
(StataCorp LP). P values are for 2-sided tests, and the level of
statistical signiﬁcance has been set at P ≤ .05. Cytokine mea-
surements of zero were replaced by the lowest detectable limit
in ratio calculations and log transformations. The correlations
between cytokine levels were investigated using Spearman
rank correlations. After adjusting for sex, delivery transmission
season, thalassemia, sickle cell trait, birth weight, maternal gra-
vidity, and placental malaria at delivery, we calculated the haz-
ard ratios (HR) for time to ﬁrst SMA event with log(e) cytokine
concentrations dichotomized at the median, by quartile, and
per standard deviation (SD) increase. Clustering at the village
level was accounted for using shared frailties [26]. For IL-4
and IFN-γ, the hazard ratio for incident SMAwas compared be-
tween individuals with and without detectable cytokine levels.
Floating absolute risks were used to assess the shapes of associ-
ations across quartiles [27]. Inﬂammatory mediators with stat-
istically signiﬁcant log-linear associations with SMA (<60 g/L)
were further analyzed by subgroup.
RESULTS
Out of 882 participants followed up, 37 children experienced
WHO SMA (Hb < 50 g/L), and 71 experienced standard SMA
(Hb < 60 g/L) (Figure 2). The median age at the time of primary
SMA event was 34.3 weeks for both case deﬁnitions. The base-
line measurements were similar between SMA cases (Hb < 60 g/
L) and noncases except that cases were statistically signiﬁcantly
less likely to live in households with insecticide-treated net
(ITN) use and more likely, albeit nonsigniﬁcantly, to be born
to mothers with placental malaria at delivery (Table 1). No stat-
istically signiﬁcant differences in baseline covariates were ob-
served between children with and without complete data.
Cord blood cytokines and receptors were measured in 783
children. The number of measurements at levels detectable by
the immunoassays were low for IL-4 (10.9%, n = 85) and IFN-
γ (20.6%, n = 161). Measured biomarker values were generally
Figure 2. Cumulative SMA incidence by case deﬁnition (N = 882 at
baseline). Abbreviations: SMA, severe malarial anemia; WHO, World
Health Organization.
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positively correlated, with the highest correlation between TNF
and IL-1β (Spearman correlation coefﬁcient: 0.65) (Supplemen-
tary Table 1). TNF, TNF-RI, IL-1β, and IL-5 levels were statisti-
cally signiﬁcantly lower and TNF-RII levels were statistically
signiﬁcantly higher in children who developed SMA (Table 1).
In total, 743 children had complete covariate data and were
included in the survival analyses. Overall, no associations were
found between cord blood IL-4, IL-6, IL-10, and IFN-γ and
SMA risk. Comparing participants with detectable and unde-
tectable levels, the fully adjusted HR (95% CI) for IL-4 and
IFN-γ were: IL-4, WHO: 0.22 (.03, 1.66), Standard: 0.39 (.12,
1.25); and IFN-γ, WHO: 1.10 (.47, 2.54), Standard: 0.89 (.46,
1.71). After dichotomizing the data at the median, low levels
of TNF, TNF-RI, IL-1β, and IL-5 and high levels of TNF-RII
Table 1. Participant Characteristics at Delivery by SMA Status (Hb < 60 g/L)
Characteristic N
SMA Cases Noncases
P ValueaN (%) or Median (IQR) N (%) or Median (IQR)
Questionnaire data Sex 882 .958
Male 37 (52.1%) 420 (51.8%)
Female 34 (47.9%) 391 (48.2%)
Transmission season 882 .517
Low 39 (54.9%) 413 (50.9%)
High 32 (45.1%) 398 (49.1%)
Household ITN use 882 .033
No 43 (60.6%) 384 (47.3%)
Yes 28 (39.4%) 427 (52.7%)
Biological measurements Thalassemia 821 .141
α2/ α2 40 (58.8%) 350 (46.5%)
α2/ α3.7 21 (30.8%) 314 (41.7%)
α3.7/ α3.7 7 (10.3%) 89 (11.8%)
Sickle cell trait 861 .116
AA 64 (90.1%) 655 (82.9%)
AS 7 (9.9%) 135 (17.1%)
Birth weight (kilograms) 880 3.2 (2.8–3.5) 3.2 (2.9–3.5) .607
Maternal characteristics Maternal gravidity 882 .267
Primigravid 15 (21.1%) 239 (29.5%)
Secundigravid 20 (28.1%) 181 (22.3%)
Multigravid 36 (50.7%) 391 (48.2%)
Maternal age (years) 882 24 (21–30) 25 (20–30) .988
Any IPTp use 820 .883
No 57 (86.4%) 656 (87.0%)
Yes 9 (13.6%) 98 (13.0%)
Placental malaria 882 .081
No 57 (80.3%) 710 (87.5%)
Yes 14 (19.7%) 101 (12.5%)
Placental parasite density (% of
infected red blood cells)
115 1.4 (0.9, 2.0) 1.2 (0.6, 4.6) .9831
Biomarker values TNF (pg/mL) 783 97.7 (43.4–150.5) 122.7 (72.5–183.8) .0042
TNF-RI (pg/mL) 783 1472.0 (1138.8–2588.3) 2182.8 (1572.1–2896.8) .0005
TNF-RII (pg/mL) 783 528.8 (332.8–1192.4) 469.6 (322.8–669.1) .0358
IL-1β (pg/mL) 783 3.0 (0.8–5.9) 6.4 (3.2–12.1) .0001
IL-4 (pg/mL) 783 0 (0–0) 0 (0–0) .1528
IL-5 (pg/mL) 783 1.7 (0.4–3.4) 2.8 (1.0–5.4) .0024
IL-6 (pg/mL) 783 6.2 (2.1–16.1) 7.0 (2.3–18.7) .561
IL-10 (pg/mL) 783 3.7 (1.7–6.1) 3.5 (1.5–6.0) .6317
IFN-γ (pg/mL) 783 0 (0–0) 0 (0–0) .4891
Abbreviations: IFN-γ, interferonγ; IL, interleukin; IQR, interquartile range; ITN, insecticide-treated net; SMA, severe malarial anemia; TNF, tumor necrosis factor.
a P values are from Kruskal–Wallis and χ2 tests as appropriate.
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were associated statistically signiﬁcantly and respectively with
approximately 3-fold, 2-fold, 8-fold, 4-fold, and 3-fold in-
creased risks of WHO-deﬁned SMA (Table 2). The associations
were materially consistent, albeit attenuated, for SMA cases by
the standard deﬁnition. Investigating the associations by quar-
tile of the log(e) concentrations showed that the proinﬂam-
matory mediators TNF, TNF-RI, IL-1β, and the ratio of TNF
to IL-10 were inversely and approximately linearly associated
with SMA risk (Figure 3). Overall, the shapes of the associations
were generally consistent across both the WHO and standard
deﬁnitions with the exception of TNF-RII. Comparing the
SMA risk per 1-SD increases in biomarker level, cord blood
IL-1β is the most strongly associated with SMA risk (Table 3).
The HR per 1-SD increase of TNF, TNF-RI, and IL-1β did not
vary signiﬁcantly when stratiﬁed across participant-level char-
acteristics (Figure 4, Supplementary Figures 1 and 2).
DISCUSSION
The ﬁndings of the current analysis support the hypothesis that
the prenatal experience can contribute to pediatric susceptibility
to SMA. Although previous reports on markers of inﬂammation
in children with SMA have been restricted to analyses of genetic
variants and the cross-sectional examination of cytokine levels
in acute episodes, the present study provides evidence that in-
nate inﬂammatory mediator concentrations at birth are associ-
ated with a child’s subsequent risk of SMA. We found that cord
blood cytokine levels were generally positively correlated with
the highest correlation between proinﬂammatory cytokines.
We also demonstrated that there are inverse associations
between concentrations of proinﬂammatory cytokines at birth
and risk of SMA. TNF, TNF-RI, and IL-1β conferred approxi-
mately log-linear protective effects that were robust to stratiﬁca-
tion by established risk factors. These results are consistent with
earlier ﬁndings that showed high cord blood levels of TNF and
IL-1β are protective against generalized severe malaria [25]. In
sum, these ﬁndings provide evidence that pediatric malarial dis-
ease has fetal origins.
We hypothesize that suboptimal conditions, resulting from
maternal stress, infection, or dietary restriction, during critical
periods of fetal development could lead to stable alterations in
gene expression associated with homeostatic changes to circu-
lating cytokine levels and inﬂammatory response to parasitic
products and, thereby, heighten an individual’s susceptibility
to SMA. Epidemiological and experimental animal model stud-
ies have consistently demonstrated that fetal malnutrition and
overexposure to glucocorticoids can developmentally program
adult diseases, such as diabetes, hypertension, and anxiety,
and are linked to a range of physiological adaptations including
modulation of the production and regulation of cytokines [18].
In a rat model of maternal stress, offspring exposed to higher in
utero concentrations of glucocorticoids had increased plasma
levels of proinﬂammatory cytokines TNF and IL-1β at 6 months
[19]. Similarly, rats that were prenatally exposed to bacterial
lipopolysaccharide mount an exaggerated IL-1β response from
CD11b+-enriched macrophages and microglia to later stimula-
tion in adulthood [20]. Additionally, rats that were fed protein-
restricted diets during pregnancy gave birth to offspring with
epigenetic modiﬁcations, altered hypothalamic-pituitary-adre-
nal (HPA) axis sensitivity, and modiﬁed proinﬂammatory cyto-
kine regulation via glucocorticoid resistance [28]. Although the
generalizability of these experimental studies of noncom-
municable diseases is limited, it is biologically plausible that
analogous adaptations could developmentally prime malaria
susceptibility.
The results of the current study support a malarial model of
fetal programming by demonstrating a strong, dose-response
effect, which is robust to stratiﬁcation by known risk factors,
and speciﬁc to cytokines that are well-established mediators of
analogous neuroendocrinological homeostatic processes. Al-
though the current ﬁndings do not causally implicate speciﬁc
intrauterine exposures in the etiology, these results highlight
the potential value of further investigation into the relation of
SMAwith maternal stressors, epigenetic modiﬁcations, and ste-
roid hormone exposures. Broadly, these ﬁndings align with the
mounting research that children exposed to malaria infections
in utero have altered cytokine responses to later exposure to ma-
larial antigens. Additional research is needed to distinguish
whether developmental programming effects of maternal infec-
tion could be operating in parallel or synergistically with the
prenatal sensitization and tolerization to blood-stage antigens
that has been observed in other endemic regions [21–24].
Table 2. Risk of SMA for High vs Low Concentrations of Log(e)
Biomarker Value (N = 743)
Biomarker
WHO SMA
(Hb < 50 g/L)
Standard SMA
(Hb < 60 g/L)
HR (95% CI)a,b P Valuec HR (95% CI)a,b P Valuec
TNF 0.35 (.17, .76) .008 0.64 (.39, 1.05) .079
TNF-RI 0.44 (.21, .91) .026 0.55 (.33, .92) .023
TNF-RII 2.97 (1.39, 6.36) .005 1.45 (.89, 2.38) .138
IL-1β 0.13 (.05, .38) <.001 0.33 (.19, .59) <.001
IL-5 0.25 (.11, .58) .001 0.53 (.32, .90) .018
IL-6 0.98 (.51, 1.89) .948 0.89 (.55, 1.45) .640
IL-10 1.26 (.65, 2.47) .494 1.24 (.75, 2.02) .400
TNF/IL-10 0.38 (.18, .79) .010 0.54 (.32, .90) .018
Abbreviations: CI, confidence interval; HR, hazard ratio; IL, interleukin; SMA,
severe malarial anemia; TNF, tumor necrosis factor; WHO, World Health
Organization.
a Biomarker dichotomized at the median.
b Adjusted for village, sex, delivery transmission season, thalassemia, sickle
cell trait, birth weight, maternal gravidity, and placental malaria status.
c P values are from Wald tests.
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Figure 3. Risk of SMA by quartile of log(e) biomarker value after adjustment for village, sex, delivery transmission season, thalassemia, sickle cell trait, birth
weight, maternal gravidity, and placental malaria status. (N = 743) Black squares and green triangles represent HR for WHO (Hb < 50 g/L) and standard (Hb <
60 g/L) deﬁnitions respectively. The P values for heterogeneity are: (A) TNF (WHO: P = .0054; Standard: P = .0239), (B) TNF-RI (WHO: P = .0004; Standard:
P = .0002), (C) TNF-RII (WHO: P = .0022; Standard: P = .1192), (D) IL-1β (WHO: P = .0001; Standard: P < .0001) (E ) IL-5 (WHO: P = .0145; Standard: 0.0739),
(F ) IL-6 (WHO: P = .4209; Standard: P = .9491), (G) IL-10 (WHO: .6585; Standard: .8485), and (H) TNF/ IL-10 (WHO: P = .0487; Standard: P = .0490). Abbreviations:
CI, conﬁdence interval; HR, hazard ratio; IL, interleukin; SMA, severe malarial anemia; TNF, tumor necrosis factor; WHO, World Health Organization.
Cord Blood Risk Markers of Malarial Anemia • JID 2015:211 (1 February) • 441
Further work is also needed to discern if high maternally de-
rived glucocorticoids immunosuppress fetal production of
proinﬂammatory cytokines and, thus, whether low cord blood
levels of TNF or IL-1β could serve as early markers for poor reg-
ulatory control of the inﬂammatory response to parasitic prod-
ucts. Notably, the results, which show lower ratios of TNF/IL-10
at birth are associated with SMA in early life, directly contrast
with the previous ﬁndings that TNF/IL-10 ratios are higher dur-
ing acute SMA events and underscore the importance of under-
standing the balance of the inﬂammatory milieu over the early
life course [10, 11, 13].
The ﬁndings of this study also reinforce interest in the com-
plex relationship between high proinﬂammatory cytokine levels
and SMA. Previously, Kabyemela et al [25] found that cord
blood levels of TNF and IL-1β levels positively correlate with
levels during the ﬁrst year and that high cord blood IL-1β levels
are associated with lower average parasite densities in infancy.
Elevated proinﬂammatory cytokines may play a vital role in
controlling parasitemia in the early response to malaria infec-
tion, clearing infected erythrocytes, and inducing cell-mediated
immunity. However, if, in acute episodes, the host response to
these endogenous pyrogens is inadequately abrogated by the
HPA axis and antiinﬂammatory mediators, they may trigger
pathological rather than protective outcomes.
While prenatal exposures may inﬂuence SMA susceptibility,
the current ﬁndings do not preclude the importance of host ge-
netics. However, the generally positive correlations between all
cytokine levels suggest systemic differences, rather than cyto-
kine-speciﬁc promoter mutations, are inﬂuencing cord blood
expression. Moreover, existing investigations have found only
limited evidence for genetic conditioning of SMA through pro-
moters of the cytokines relevant to this analysis. TNF−238A has
been correlated with TNF/IL-10 >1, which has been thought to
mediate SMA and SMA risk [11, 29]. In addition, the IL-1β
promoter haplotype−31C/−511A is associated with statistically sig-
niﬁcantly decreased circulating IL-1β and increased risk of SMA
(OR (95% CI), 1.98 (1.55, 2.29)) [14]. Future research should
continue to prioritize the study of speciﬁc genetic markers for
polymorphisms in cytokine production in large-scale genetic
studies, such as those undertaken by the MalariaGEN (http://
www.malariagen.net/), although elucidating these relationships
could be challenging due to the potentially pleiotropic nature of
cytokine promoters.
The strengths and limitations of the current study warrant
consideration. This prospective cohort study had both a high
response and retention rate and provides the ﬁrst prospective
investigation of cord blood cytokines and risk of SMA. Cases
of SMA were robustly ascertained during clinical visits with
blood smears and Hb measurements. Assay methods were sim-
ilar to those used in previous studies on cytokines and SMA.
Although the study size is relatively large among malarial ane-
mia studies, the number of cases of SMA that ﬁt the criteria of
the more stringent WHO case deﬁnition (Hb < 50 g/L) was
small (n = 37). For stratiﬁcation purposes, the broader standard
deﬁnition (Hb < 60 g/L) of SMA was used despite the potential
for decreasing the speciﬁcity of the examined relationships. Al-
though the associations between cytokines and SMA are gener-
ally consistent across the deﬁnitions, the statistically signiﬁcant
protective effect of IL-5 and pathogenic effect of TNF-RII were
only discernible when the deﬁnition was limited to the WHO-
deﬁned cases. Conversely, the risk of SMA per 1-SD increase in
TNF and TNF/IL-10 lost statistical signiﬁcance using the
stricter deﬁnition. To address this issue, future studies should
aim to accrue larger sample sizes, which would also allow for
comparative analyses with other severe malaria syndromes,
such as cerebral malaria, that are uncommon in this population,
and to allow a longer duration of follow-up, which would pro-
vide greater time to observe SMA events in individuals who are
Table 3. Risk of SMA Per 1-SD Increase in Log(e) Biomarker Value (N = 743)
Biomarker SD
WHO SMA (Hb < 50 g/L) Standard SMA (Hb < 60 g/L)
HR (95% CI)a P Valueb HR (95% CI)a P Valueb
TNF 1.12 0.81 (.65, 1.02) .070 0.83 (.70, .98) .031
TNF-RI 0.64 0.76 (.62, .92) .006 0.74 (.63, .87) <.001
TNF-RII 1.75 2.33 (1.08, 5.03) .030 1.26 (.88, 1.80) .201
IL-1β 1.80 0.50 (.40, .62) <.001 0.58 (.49, .69) <.001
IL-5 1.97 0.66 (.50, .88) .004 0.81 (.65, 1.01) .061
IL-6 1.71 0.76 (.53, 1.10) .148 0.93 (.73, 1.18) .543
IL-10 1.84 1.11 (.79, 1.58) .548 1.08 (.84, 1.39) .561
TNF/IL-10 1.91 0.75 (.53, 1.05) .089 0.78 (.61, 1.00) .053
Abbreviations: CI, confidence interval; HR, hazard ratio; IL, interleukin; SD, standard deviation; SMA,severe malarial anemia; TNF, tumor necrosis factor; WHO,World
Health Organization.
a Adjusted for village, sex, delivery transmission season, thalassemia, sickle cell trait, birth weight, maternal gravidity, and placental malaria status.
b P values are from Wald tests.
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included in the study but for whom SMA events are not yet ob-
served by the conclusion of the study. There is also a risk that
residual confounding, such as pregnancy malaria episodes that
were resolved by the time of parturition, could lead to conser-
vative effect estimates. Although published ﬁndings have been
conﬂicting to date (reviewed in [30, 31]), another unmeasured
variable worth consideration is comorbid parasitic infection
(eg, an intestinal helminth infection) at the time of the SMA ep-
isode that could alter a child’s susceptibility to malaria infection
and contribute to the etiology of anemia. Furthermore, it would
be valuable to investigate any contribution by nonmalarial par-
asitic infections in the pregnant mother on the child’s cord
blood cytokine expression. The study design inherently intro-
duces a risk of selection bias because only 50.2% of Tanzanian
deliveries occur in health facilities, and women who use health
facilities are more likely to be younger, wealthier, better educat-
ed, and urban dwellers [32]. Finally, although the majority of
SMA cases occur in regions of persistent malaria transmission,
it is unknown whether the current ﬁndings will be generalizable
across regions with seasonally varying entomological inocula-
tion rates.
Identifying characteristics that contribute to pathological or
protective outcomes following malaria infection can help to elu-
cidate etiological pathways and has the potential to inform the
rational design of vaccines and therapeutic measures. This study
demonstrates that there is an inverse and approximately log-
linear association between proinﬂammatory cytokine levels in
cord blood and SMA risk over the ﬁrst 4 years of life. These
ﬁndings highlight an interventional window of opportunity
that precedes the dysregulation in inﬂammatory mediators
Figure 4. Risk of standard SMA (Hb < 60 g/L) per 1-SD increase in log(e) IL-1β concentration by several participant level characteristics (N = 743). HR is
adjusted for the following excluding the stratiﬁed covariate: village, sex, delivery transmission season, thalassemia, sickle cell trait, birth weight, maternal
gravidity, and placental malaria status. *P values are from likelihood ratio tests. Abbreviations: CI, conﬁdence interval; HR, hazard ratio; IL, interleukin; SD,
standard deviation; SMA, severe malarial anemia.
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that develops acutely during an infection. In addition, this study
lends support to the hypothesis that there may be fetal origins of
malarial disease. Further study is needed to identify biological
mechanisms that determine fetal cytokine proﬁles and to un-
derstand the regulation of cytokine concentrations over time.
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